Investigating a biomarker's role in heart surgery outcomes
Association Between Soluble ST2 and Cardiovascular Outcome After Cardiovascular Surgery
This study is trying to see if a specific biomarker called sST2 can help predict heart surgery outcomes for patients with different heart conditions.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Nanjing Medical University Academic / other |
| Locations | 1 site (Nanjing, Jiangsu) |
| Trial ID | NCT04460131 on ClinicalTrials.gov |
What this trial studies
This observational study examines the relationship between soluble suppression of tumorigenicity 2 (sST2), a biomarker associated with myocardial remodeling and fibrosis, and cardiovascular events in patients undergoing cardiac surgery. By measuring the levels of sST2, the study aims to understand how this biomarker correlates with the risk of cardiovascular morbidity and mortality following surgical interventions. The study focuses on patients with various heart conditions requiring surgical treatment, including congenital heart disease, valvular heart disease, arrhythmias, aortic dissection, and coronary heart disease.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who require surgical intervention for specific heart conditions.
Not a fit: Patients under 18 years old, pregnant women, or those with severe renal dysfunction may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help identify patients at higher risk for cardiovascular events after heart surgery, leading to improved patient management and outcomes.
How similar studies have performed: While the specific approach of using sST2 in this context may be novel, similar studies have explored biomarkers in cardiovascular outcomes with varying degrees of success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age ≥ 18 years * Congenital heart disease requiring surgery * Valvular heart disease requiring surgery * Arrhythmia requiring surgery * Aortic dissection requiring surgery * Coronary heart disease requiring surgery Exclusion Criteria: * age \<18 years * pregnancy * severe renal dysfunction (creatinine \>200µmol/L) * not capable of understanding or signing informed consent.
Where this trial is running
Nanjing, Jiangsu
- The first affiliated hospital of nanjing medical university — Nanjing, Jiangsu, China (Recruiting)
Study contacts
- Study coordinator: Yong-feng Shao
- Email: yfshaojph@sina.com
- Phone: +8618801281613
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.